Last edition
News about "Kevin Eggan"
BioMarin, n-Lorem Partner to Develop First Investigational Therapy for ReNU Syndrome
BioMarin and the n-Lorem Foundation have partnered to develop an investigational antisense oligonucleotide therapy targeting the most common genetic variant associated with ReNU syndrome, a rare neurodevelopmental disorder with no approved treatments.
Kevin Eggan | 28/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members